Aktis Oncology AKTS
NASDAQ AKTS
$16.62 +0.34 (+2.09%)
At close: Nov 13, 2026 · 4:00 PM EST

Aktis Oncology (AKTS) Price to Sales (2026)

Updated

Aktis Oncology's (AKTS) Price to Sales came in at 87.48 for Q3 2026, down 48.9% from the prior quarter.

Analysis

Aktis Oncology (AKTS) Price to Sales (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn
5 Novartis Ag 306.35 Bn 279.93 Bn -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn
10 Aktis Oncology 895.95 Mn 335.72 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 87.48
Jun 30, 2026 178.34
API Access

Aktis Oncology Price to Sales API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=price-to-sales&ticker=AKTS&period=max&api_key=YOUR_API_KEY